Vanda Pharmaceuticals (VNDA) Current Assets (2010 - 2026)

Vanda Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $293.2 million in Q1 2026.

• Quarterly Current Assets fell 28.13% year-over-year to $293.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293.2 million (down 28.13% YoY) and the FY2025 annual result came in at $347.3 million, down 20.88% from the prior year.
• Current Assets retreated to $293.2 million in Q1 2026 per VNDA's latest filing, from $347.3 million in the prior quarter.
• Over five years, Current Assets peaked at $536.6 million in Q3 2023 and troughed at $293.2 million in Q1 2026.
• A 5-year average of $447.8 million and a median of $439.2 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2026: Current Assets grew 16.87% in 2022, then decreased 28.13% in 2026.
• Over 5 years, Current Assets stood at $519.3 million in 2022, then retreated by 16.63% to $432.9 million in 2023, then rose by 1.37% to $438.9 million in 2024, then retreated by 20.88% to $347.3 million in 2025, then slipped by 15.58% to $293.2 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $293.2 million, $347.3 million, and $367.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.